Union Therapeutics starts phase II trial of nasal spray for Covid-19 patients

Biotech company Union Therapeutics is testing its candidate niclosamid as a nasal spray for patients infected with Covid-19 who are either asymptomatic or mildly symptomatic in a phase II study.

Photo: Union Therapeutics / PR

The Danish biotech company Union Therapeutics has enrolled the first patient in its phase II trial of drug candidate niclosamid as a treatment for Covid-19 patients, it reports in a press release.

According to the company, the study's primary goal is to investigate whether niclosamid administered intranasally can prevent symptom progression in the enrolled patients who have been infected with Covid-19 but who have no symptoms or mild symptoms when they join the study.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs